Item 2.02. Results of Operations and Financial Condition.

On November 8, 2022, Sutro Biopharma, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2022. A copy of the press release is attached as Exhibit 99.1 to this report.

The information furnished with Item 2.02 of this report, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended (the "Securities Act"), except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits



(d) Exhibits.

Exhibit
  No.                                   Description

            Press release issued by Sutro Biopharma, Inc. regarding its financial
99.1      results for the period ended September 30, 2022, dated November 8,
          2022.
104       Cover Page Interactive Data File (embedded within the Inline XBRL
          document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses